Bispecific Trispecific Tetraspecific Multispecific Antibodies Market Size Clinical Trials Approved Antibody Sales Price Insight Antibodies Market By Region Indication Companies
28 août 2024 13h24 HE
|
KuicK Research
Delhi, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Global Multispecific Antibodies Market, Drug Sales, Price and Clinical Trials Insight 2029 Report Highlights: Global and Regional Market AnalysisGlobal...
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
07 déc. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
08 juin 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Teneobio Licenses Oncology Multispecific Product to Janssen
30 sept. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
15 juil. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology
09 juil. 2018 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and...
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
08 janv. 2018 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...